Price cuts secure NHS place for MS drugs
NICE is now backing a trio of therapies to treat relapsing remitting forms of multiple sclerosis after price cuts enabled the cost regulator to endorse their routine use on the NHS.
Read More
Tag: Extavia
NICE proposes restricting MS therapies
Novartis’ Extavia is the only beta interferon being endorsed by the National Institute for Health and Care Excellence as a cost-effective treatment option for multiple sclerosis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
